BR122019001455B1 - vacina contra o vírus da doença equina africana - Google Patents

vacina contra o vírus da doença equina africana Download PDF

Info

Publication number
BR122019001455B1
BR122019001455B1 BR122019001455-8A BR122019001455A BR122019001455B1 BR 122019001455 B1 BR122019001455 B1 BR 122019001455B1 BR 122019001455 A BR122019001455 A BR 122019001455A BR 122019001455 B1 BR122019001455 B1 BR 122019001455B1
Authority
BR
Brazil
Prior art keywords
ahsv
virus
seq
recombinant
vector
Prior art date
Application number
BR122019001455-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Jules Maarten Minke
Jean-Christophe Audonnet
Alan John Guthrie
Nigel James Maclachlan
Jiansheng Yao
Original Assignee
Merial, Inc.
The Regents Of The University Of California
University Of Pretoria
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41818403&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR122019001455(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merial, Inc., The Regents Of The University Of California, University Of Pretoria filed Critical Merial, Inc.
Publication of BR122019001455B1 publication Critical patent/BR122019001455B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12111—Orbivirus, e.g. bluetongue virus
    • C12N2720/12122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12111—Orbivirus, e.g. bluetongue virus
    • C12N2720/12134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR122019001455-8A 2008-10-24 2009-10-22 vacina contra o vírus da doença equina africana BR122019001455B1 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US10807508P 2008-10-24 2008-10-24
US61/108,075 2008-10-24
US16351709P 2009-03-26 2009-03-26
US61/163,517 2009-03-26
BRPI0920622-1A BRPI0920622B1 (pt) 2008-10-24 2009-10-22 vacina contra o vírus da doença equina africana
PCT/US2009/061669 WO2010048394A2 (en) 2008-10-24 2009-10-22 Vaccine against african horse sickness virus

Publications (1)

Publication Number Publication Date
BR122019001455B1 true BR122019001455B1 (pt) 2021-01-19

Family

ID=41818403

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122019001455-8A BR122019001455B1 (pt) 2008-10-24 2009-10-22 vacina contra o vírus da doença equina africana
BRPI0920622-1A BRPI0920622B1 (pt) 2008-10-24 2009-10-22 vacina contra o vírus da doença equina africana

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0920622-1A BRPI0920622B1 (pt) 2008-10-24 2009-10-22 vacina contra o vírus da doença equina africana

Country Status (19)

Country Link
US (3) US8168200B2 (https=)
EP (1) EP2358742B1 (https=)
JP (1) JP2012506699A (https=)
KR (1) KR101719005B1 (https=)
CN (1) CN102245627A (https=)
AP (1) AP3334A (https=)
AR (1) AR074055A1 (https=)
AU (1) AU2009308331C1 (https=)
BR (2) BR122019001455B1 (https=)
CA (1) CA2741333C (https=)
CL (1) CL2011000922A1 (https=)
EA (1) EA024111B1 (https=)
ES (1) ES2681693T3 (https=)
MX (1) MX2011004219A (https=)
NZ (2) NZ598605A (https=)
PL (1) PL2358742T3 (https=)
PT (1) PT2358742T (https=)
WO (1) WO2010048394A2 (https=)
ZA (1) ZA201103031B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101719005B1 (ko) * 2008-10-24 2017-03-22 메리얼 인코포레이티드 아프리카 마역 바이러스에 대한 백신
EP3466443B1 (en) 2012-02-14 2020-12-16 Boehringer Ingelheim Animal Health USA Inc. Recombinant poxviral vectors expressing both rabies and ox40 proteins, and vaccines made therefrom
WO2016071850A1 (en) * 2014-11-04 2016-05-12 Deltamune (Pty) Limited Live attenuated african horsesickness virus
US11233998B2 (en) 2015-05-29 2022-01-25 Qualcomm Incorporated Coding data using an enhanced context-adaptive binary arithmetic coding (CABAC) design
EA202092165A1 (ru) * 2018-03-19 2021-02-25 Бёрингер Ингельхайм Ветмедика Гмбх Новый ehv сайт инсерции ul43
US12581092B2 (en) 2022-03-03 2026-03-17 Qualcomm Incorporated Temporal initialization points for context-based arithmetic coding
CN116041447A (zh) * 2022-12-29 2023-05-02 北京亿森宝生物科技有限公司 一种检测非洲马瘟病毒的试剂盒及其应用
CN116656731B (zh) * 2023-05-25 2024-04-12 军事科学院军事医学研究院军事兽医研究所 一种表达非洲猪瘟病毒多种蛋白的重组金丝雀痘病毒及其构建方法
EP4520797A1 (en) 2023-07-07 2025-03-12 Chukyo Yushi Co., Ltd. Dispersion
CN117737310B (zh) * 2024-01-26 2024-07-16 中国农业科学院北京畜牧兽医研究所 非洲马瘟和西尼罗病毒的双重实时荧光mira检测引物探针组、试剂盒及方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5505941A (en) * 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5843456A (en) 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
DE69233158T2 (de) * 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
ZA976424B (en) * 1996-07-05 1999-01-22 Agricultural Research Council Nucleic acid sequences coding for african horsesickness virus outer capsid components
FR2775601B1 (fr) * 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
FR2776928B1 (fr) * 1998-04-03 2000-06-23 Merial Sas Vaccins adn adjuves
US7740863B2 (en) * 2001-04-06 2010-06-22 Merial Recombinant vaccine against West Nile Virus
US7862821B2 (en) * 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
KR101719005B1 (ko) * 2008-10-24 2017-03-22 메리얼 인코포레이티드 아프리카 마역 바이러스에 대한 백신

Also Published As

Publication number Publication date
AU2009308331B2 (en) 2014-08-21
EA024111B1 (ru) 2016-08-31
MX2011004219A (es) 2011-09-22
WO2010048394A3 (en) 2010-08-19
KR101719005B1 (ko) 2017-03-22
NZ598605A (en) 2014-04-30
EP2358742A2 (en) 2011-08-24
EA201100674A1 (ru) 2011-12-30
JP2012506699A (ja) 2012-03-22
AR074055A1 (es) 2010-12-22
NZ592388A (en) 2012-03-30
AP3334A (en) 2015-07-31
US20100119546A1 (en) 2010-05-13
ES2681693T3 (es) 2018-09-14
CA2741333A1 (en) 2010-04-29
CN102245627A (zh) 2011-11-16
BRPI0920622A2 (pt) 2016-10-04
US20140120133A1 (en) 2014-05-01
US20120114691A1 (en) 2012-05-10
AU2009308331A1 (en) 2010-04-29
KR20110092281A (ko) 2011-08-17
WO2010048394A2 (en) 2010-04-29
EP2358742B1 (en) 2018-02-28
PL2358742T3 (pl) 2018-08-31
BRPI0920622B1 (pt) 2019-11-12
CL2011000922A1 (es) 2011-09-16
CA2741333C (en) 2018-02-13
PT2358742T (pt) 2018-06-04
AP2011005954A0 (en) 2011-10-31
US8168200B2 (en) 2012-05-01
BRPI0920622A8 (pt) 2019-02-05
ZA201103031B (en) 2014-03-26
AU2009308331C1 (en) 2015-07-09

Similar Documents

Publication Publication Date Title
EP2358742B1 (en) Vaccine against african horse sickness virus
TWI399213B (zh) 抗藍舌病病毒之重組疫苗
ES2787902T3 (es) Vacunas contra FMDV vectorizadas con adenovirus recombinantes y usos de las mismas
EP2861248B1 (en) Reassortant btv and ahsv vaccines
US20170087244A1 (en) Canine Parvovirus (CPV) Virus-like Particle (VLP) Vaccines and uses thereof
BR112014023414B1 (pt) Vacina de herpesvirus-1 equino recombinante contendo uma glicoproteína c mutante e seus usos
BR112014001287B1 (pt) vacina recombinante do vírus da leucemia felina contendo gene otimizado do envelope do vírus da leucemia felina
AU2014218358B2 (en) Vaccine against african horse sickness virus
HK1157360B (en) Vaccine against african horse sickness virus
HK1157360A (en) Vaccine against african horse sickness virus
CN108135997A (zh) Fcv重组疫苗及其用途
BR112017005833B1 (pt) Vacinas recombinantes fmdv e seus usos
HK1209326B (en) Reassortant btv and ahsv vaccines
BR112018006567B1 (pt) Vacinas de partículas semelhantes a vírus (vlp) do parvovirus canino (cpv) e seus usos

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B25C Requirement related to requested transfer of rights

Owner name: MERIAL, INC. (US) ; THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) ; UNIVERSITY OF PRETORIA (ZA)

Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 870210030666 DE 01/04/2021, E NECESSARIO ESCLARECER A DIVERGENCIA ENTRE O NOME DA EMPRESA QUE CONSTA NO DOCUMENTO DE CESSAO APRESENTADO COMO CESSIONARIA E O NOME DA EMPRESA QUE APARECE NA PROCURACAO. ALEM DISSO, E PRECISO APRESENTAR A GUIA DE CUMPRIMENTO DE EXIGENCIA.

B25B Requested transfer of rights rejected

Owner name: MERIAL, INC. (US) ; THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) ; UNIVERSITY OF PRETORIA (ZA)

Free format text: INDEFERIDO O PEDIDO DE TRANSFERENCIA CONTIDO NA PETICAO 870210030666 DE 01/04/2021, POR AUSENCIA DE CUMPRIMENTO DA EXIGENCIA PUBLICADA NA RPI NO 2630, DE 01/06/2021.

B25A Requested transfer of rights approved

Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) ; UNIVERSITY OF PRETORIA (ZA) ; BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC. (US)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) ; UNIVERSITY OF PRETORIA (ZA) ; MERIAL, INC. (US)

Free format text: ANULADA A PUBLICACAO CODIGO 25.1 NA RPI NO 2663 DE 18/01/2022 POR TER SIDO INDEVIDA.

B25A Requested transfer of rights approved

Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) ; UNIVERSITY OF PRETORIA (ZA) ; BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC. (US)